Labcorp Holdings D&A increased by 4.1% to $75.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.6%, from $69.60M to $75.60M. Over 4 years (FY 2021 to FY 2025), D&A shows relatively stable performance with a -1.4% CAGR.
Analysis
How to read this metric
Higher levels often indicate significant recent capital investment or large historical acquisitions, while lower levels may suggest aging assets.
Detailed definition
Depreciation and amortization represent the systematic allocation of the cost of tangible and intangible assets over the...
Peer comparison
High in capital-intensive industries like healthcare and manufacturing; peers often report this as a significant non-cash drag on earnings.
depreciation_and_amortizationHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $92.40M | $92.20M | $19.90M | $67.10M | $49.80M | $49.00M | $44.60M | $53.40M | $51.50M | $55.70M | $59.20M | $60.10M | $62.20M | $63.70M | $70.40M | $69.60M | $68.30M | $69.50M | $72.60M | $75.60M |
| QoQ Change | — | -0.2% | -78.4% | +237.2% | -25.8% | -1.6% | -9.0% | +19.7% | -3.6% | +8.2% | +6.3% | +1.5% | +3.5% | +2.4% | +10.5% | -1.1% | -1.9% | +1.8% | +4.5% | +4.1% |
| YoY Change | — | — | — | — | -46.1% | -46.9% | +124.1% | -20.4% | +3.4% | +13.7% | +32.7% | +12.5% | +20.8% | +14.4% | +18.9% | +15.8% | +9.8% | +9.1% | +3.1% | +8.6% |
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Diagnostics | $63.10M | $65.10M | $69.10M | $61.70M | $65.40M | $66.40M | $65.30M | $63.80M |
| Biopharma Laboratory Services | — | — | — | $28.60M | $29.00M | $29.00M | $29.40M | $28.60M |
| Corporate Segment | $1.38M | $1.38M | $1.38M | — | — | — | — | — |
| Total | $62.20M | $63.70M | $70.40M | $69.60M | $68.30M | $69.50M | $72.60M | $75.60M |
Corporate Segment, Covance Drug Development are derived from annual filings.
Corporate Segment, Covance Drug Development were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
D&A at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's d&a?
- Labcorp Holdings (LH) reported d&a of $75.60M in Q1 2026.
- How has Labcorp Holdings's d&a changed year-over-year?
- Labcorp Holdings's d&a increased by 8.6% year-over-year, from $69.60M to $75.60M.
- What is the long-term trend for Labcorp Holdings's d&a?
- Over 4 years (2021 to 2025), Labcorp Holdings's d&a has grown at a -1.4% compound annual growth rate (CAGR), from $296.60M to $280.00M.
- What does d&a mean?
- The non-cash expense that spreads the cost of physical and intangible assets over their useful life.